We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid COVID-19 Antigen Tests Less Effective at Detecting SARS-CoV-2 in People with Low Virus Levels, Finds Study

By LabMedica International staff writers
Posted on 22 Oct 2020
Researchers from the Erasmus University Medical Center (Rotterdam, the Netherlands) have cautioned that not all rapid COVID-19 antigen tests that provide results within 30 minutes may be equally effective at detecting the SARS-CoV-2 virus.

Their suggestion was based on data gathered from drive through testing stations using rapid antigen detection tests (RDTs), RT-PCR and virus culture, with the aim of assessing the ability of RDTs to detect infectious cases. More...
Antigen-based assays detect specific surface proteins, or antigens, on SARS-CoV-2 particles, and are easy to use and inexpensive to produce. The researchers used five commercially available rapid antigen assays on samples from 1,754 people who had already tested positive for the SARS-CoV-2 virus with the standard PCR test, which is highly sensitive but slow.

The team found that the detection limits of the five commercially available RDTs differed considerably, impacting the translation into the detection of infectious cases. The two most sensitive tests detected the SARS-CoV-2 virus more than 97% of the time, whereas the least sensitive test detected the novel coronavirus in about 75% of the cases. All the samples came from people with COVID-19 symptoms, who tend to have high levels of the SARS-CoV-2 virus. Based on their findings, the researchers have cautioned that rapid antigen tests may be less effective at picking up the presence of the SARS-CoV-2 virus in people with low levels of the virus. The researchers have recommended careful fit-for-purpose testing before implementation of antigen RDTs in routine testing algorithms as part of the COVID-19 response.

Related Links:
Erasmus University Medical Center


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Collection and Transport System
PurSafe Plus®
New
Gold Member
Hybrid Pipette
SWITCH
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.